Proposed Rules Will Vastly Expand Trove of Clinical Trial Data Reported in U. S. Database

November 19, 2014

(Science) – The amount of clinical data that drug companies must share with the public could soon vastly expand under a U.S. regulation proposed today. Trial sponsors would need to report summary results for drugs and devices that are never approved—and not just for products that reach the market—under the proposal.